Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Mannheimia haemolytica
Boehringer Ingelheim Animal Health UK Ltd
QI02AB04
Mannheimia haemolytica
Suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle
Inactivated Bacterial Vaccine
Expired
1997-08-27
Revised: November 2018 AN: 01034/2018 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bovalto Pastobov 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: _Mannheimia haemolytica*_ type A1 antigen: leucotoxin minimum of 68 ELISA.U** _* Mannheimia haemolytica_ was formerly called _Pasteurella haemolytica_ ** 1 ELISA.U: q.s. to obtain a _Mannheimia haemolytica_ antibody titre of 1 ELISA unit in mice after two administrations of vaccine ADJUVANT(S): Aluminium (as hydroxide) ........................................................................4.2 mg EXCIPIENT(S): Thiomersal ...............................................................................................0.2 mg Excipient ............................................................................ q.s.p. 1 dose of 2 ml For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection – Milky beige 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cattle to reduce clinical signs and lesions of _ Mannheimia _ _haemolytica_* A1 induced respiratory disease. 4.3 CONTRAINDICATIONS None Revised: November 2018 AN: 01034/2018 Page 2 of 5 4.4 SPECIAL WARNINGS None 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Shake well before use. Apply usual aseptic procedures Vaccinate only healthy animals Apply usual procedures for the handling of the animals. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS In the case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Vaccination by the subcutaneous route is followed by a limited 2-5 cm local reaction (oedema developing as a nodule) that regresses within 3 weeks. Vaccination by the intramuscular route can cause a transient, diffuse oedema and slight local reaction u Read the complete document